Revolutionary products for neurodegenerative diseases
Accera’s proprietary therapeutic platform addresses the established physiological hallmark and metabolic defect of decreased cerebral glucose metabolism (DCGM) in neurodegenerative diseases such as Alzheimer’s.
Proprietary mechanism of action
Accera’s core technology is to induce a mild state of ketosis in patients with AD. Ketosis is characterized by the presence of ketone bodies in the blood. Under conditions of low glucose availability, such as during a fast, the body taps fat reserves to gen
erate ketone bodies. Studies have shown that ketone bodies can fuel up to 60% of brains total energy needs.
Accera has researched and developed substances the can induce ketosis without the need for dietary change or fasting. Axona® is an innovative non-drug prescription product designed to address this underlying pathophysiology. Axona® is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.
Clinical data supporting efficacy and safety
Clinical studies have demonstrated the feasibility of this approach. Accera is currently conducting a study with AC-1204 in mild to moderate AD under an IND throughout the US. Secured key strategic investor financing.